Markets Stifel cuts vTv Therapeutics to hold; PT to $1 from $12 Stifel downgraded vTv Therapeutics (NASDAQ:VTVT) to “hold” from “buy” and slashed its price target to $1 from $12 after the company reported negative top line results from its Phase 3 STEADFAST study in mild Alzheimer’s... April 10, 2018